Our top pick for
Evogene Ltd is a biotechnology business based in the US. Evogene shares (EVGN) are listed on the NASDAQ and all prices are listed in US Dollars. Evogene employs 143 staff and has a trailing 12-month revenue of around USD$805,000.
|52-week range||USD$0.75 - USD$10.24|
|50-day moving average||USD$7.1079|
|200-day moving average||USD$4.2348|
|Wall St. target price||USD$15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.715|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$419,000|
|Return on assets TTM||-21.52%|
|Return on equity TTM||-39.5%|
|Market capitalisation||USD$222 million|
TTM: trailing 12 months
There are currently 1.4 million Evogene shares held short by investors – that's known as Evogene's "short interest". This figure is 16.5% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting Evogene shares can be evaluated.
Evogene's "short interest ratio" (SIR) is the quantity of Evogene shares currently shorted divided by the average quantity of Evogene shares traded daily (recently around 2.1 million). Evogene's SIR currently stands at 0.66. In other words for every 100,000 Evogene shares traded daily on the market, roughly 660 shares are currently held short.
However Evogene's short interest can also be evaluated against the total number of Evogene shares, or, against the total number of tradable Evogene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evogene's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Evogene shares in existence, roughly 40 shares are currently held short) or 0.0431% of the tradable shares (for every 100,000 tradable Evogene shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evogene.
Find out more about how you can short Evogene stock.
We're not expecting Evogene to pay a dividend over the next 12 months.
Evogene's shares were split on a 1:2 basis on 19 November 2013. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evogene shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Evogene shares which in turn could have impacted Evogene's share price.
Over the last 12 months, Evogene's shares have ranged in value from as little as $0.75 up to $10.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evogene's is 0.5341. This would suggest that Evogene's shares are less volatile than average (for this exchange).
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.